Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer (Q43947658)

28 November 2017

Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer (English)

1 reference

28 November 2017

9

Olle Stål

1 reference

28 November 2017

Gizeh Pérez-Tenorio

1

1 reference

28 November 2017

Elin Karlsson

2

1 reference

28 November 2017

Marie Ahnström Waltersson

3

1 reference

28 November 2017

Birgit Olsson

4

1 reference

28 November 2017

Birgitta Holmlund

5

1 reference

28 November 2017

Bo Nordenskjöld

6

1 reference

28 November 2017

Tommy Fornander

7

1 reference

28 November 2017

Lambert Skoog

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

16 October 2010

1 reference

Breast Cancer Research and Treatment

28 November 2017

1 reference

28 November 2017

128

1 reference

28 November 2017

3

1 reference

28 November 2017

713-723

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1058-x

28 November 2017

0 references

cites work

Molecular mechanisms of mTOR-mediated translational control

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Characterization of S6K2, a novel kinase homologous to S6K1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Drosophila S6 kinase: a regulator of cell size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

The 17q23 amplicon and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Gene amplification in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Antisense inhibition of the RAD51 enhances radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Akt kinases in breast cancer and the results of adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

Amplification of HSD17B1 and ERBB2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1058-X

10.1007/S10549-010-1058-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 November 2017

0 references

1 reference